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Abstract
Objectives In people with rheumatoid arthritis (RA), mental health problems are common, but often not recognized or treated,
contributing to increased morbidity and mortality. Most studies examining the impact of mental health problems in RA have
focused on depression. We aimed to determine the association between anxiety, and disease activity and quality of life (QoL) in
people with RA.
Methods A systematic review and meta-analysis were performed. A protocol was registered with PROSPERO (CRD2-
17062580). Databases (Web of Science, PsycINFO, CINAHL, Embase, Medline) were searched for studies examining the
association between anxiety and disease activity and QoL, in adults with RA, from inception to February 2019. Primary outcome
measures were DAS28 and SF-36. Eligibility screening and data extraction were completed by two reviewers. Disagreements
were resolved by discussion or a third reviewer. Quality assessment was carried out using the Newcastle-Ottawa Scale.
Results From 7712 unique citations, 60 articles were assessed for eligibility. The final review included 20 studies involving 7452
people with RA (14 cross-sectional, 6 cohort). Eleven examined disease activity, 6 reported QoL outcome measures and 3
included both. Anxiety was associated with increased disease activity and worse QoL. Meta-analysis showed anxiety to be
correlated with increased DAS28 scores (r = 0.23, CI 0.14, 0.31) and reduced physical (r = − 0.39, CI − 0.57, − 0.20) and mental
QoL (− 0.50, CI − 0.57, − 0.43).
Conclusions Anxiety in people with RA is associated with increased disease activity and worse QoL. Improved recognition and
management of comorbid anxiety may help to improve outcomes for people with RA.
Key Points
• This is the first systematic review and meta-analysis to examine the relationship between anxiety and disease activity and QoL in people with RA.
• Anxiety was associated with higher disease activity both cross-sectionally and at up to 12-month follow-up.
• Anxiety may have a more significant impact on disease activity in early RA, highlighting the importance of early recognition and management of
comorbid anxiety.
• People with anxiety had poorer self-reported physical and mental QoL, although there was some heterogeneity in study findings, particularly for
physical QoL (I2 = 78.5%).
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Introduction
Rheumatoid arthritis (RA) is a chronic systemic condition
characterized by joint pain and inflammation, affecting
0.67% of the adult population [1]. Comorbid mental health
problems are common; the estimated prevalence of anxiety
is 14% [2], whilst prevalence estimates for depression vary
from 16.8–38.8% depending on the method of case ascertain-
ment [3], which are substantially higher than in the general
population of England (prevalence of anxiety and depression
in adults is estimated at 5.9% and 3.3% respectively) [4].
In patients with RA, comorbid anxiety and depression are
often under-recognized and under-treated [5] and are associated
with increased morbidity and mortality [6, 7]. Rathbun et al.
have proposed a bidirectional relationship between depression
and physical health in RA [8]. Low mood may influence med-
ication adherence [9], in addition to physical activity, leading to
deconditioning and increased pain [10]. Psychological factors
may also impact on disease activity by altering the immune
response, increasing pro-inflammatory cytokines and conse-
quential inflammation [11]. Reciprocally, worse physical health
can lead to depression [8].
Mental health problems can also impact on how disease
activity is assessed. People with RA and comorbid anxiety
or depression can rate their disease activity higher than their
physicians [12]. Patient-reported measures forming part of the
disease activity score in 28 joints (DAS28) are strongly influ-
enced by psychological variables [13]. Consequently, separate
reporting of the DAS28 components alongside an assessment
for anxiety or depression could aid patient management [13].
To date, most studies examining the impact of mental health
problems in RA have focused on depression. A systematic
review including 7 studies of low to moderate quality has found
that depression may be associated with increased disease activ-
ity in RA [8], whilst baseline depressive symptoms in people
with RA on biologic treatments have been linked to a reduced
improvement in DAS28 over time, compared with people with-
out depression [14]. Further studies have shown depression in
people with RA to be associatedwith reduced disease remission
[15]. QoL has also been found to be significantly reduced in
people with RA and depressive symptoms [6, 16].
When the impact of anxiety in RA has been examined, this
has often been in combination with depression. For example, a
secondary analysis of data from a randomized controlled trial
was performed to determine whether symptoms of anxiety and
depression, as assessed using the EQ-5D, predicted treatment
response [17]. Both baseline and persistent mood problems
were associated with significantly increased DAS28 scores.
However, anxiety does not always co-exist with
depression—in the general population, at least 40% of individ-
uals with anxiety do not have comorbid depression [18]. A
recent systematic review found the incidence of anxiety to be
higher in people with RA (OR 1.2, 95% CI 1.03–1.39) [19].
This is important, as although some management options over-
lap with depression [20], there are key management differences
for people with anxiety, including applied relaxation and a
higher threshold for prescription of antidepressants or anxio-
lytics [21]. As mentioned, people with RA and comorbid anxi-
ety have also been found to rate their disease activity higher than
their physician [12]. Consequently, it is important that anxiety is
recognized, both to ensure suitable psychological treatment and
to facilitate appropriate management of RA. Despite this, few
studies have examined the impact of anxiety alone in RA.
Understanding the impact of anxiety in RA on QoL and
disease activity will provide evidence to support the need to
recognize and appropriately treat anxiety in people with RA.
Consequently, a systematic review and meta-analysis were
performed, to determine the relationship between anxiety
and disease activity and QoL in patients with RA.
Materials and methods
The protocol for this systematic review was registered with
PROSPERO number CRD2-17062580 [22].
Search strategy and study eligibility
A search strategy was developed using comprehensive text
word searching of the title, abstract or keywords and database
Subject Headings, combining terms for anxiety and RA. The
search was kept broad in order to ensure that alternative de-
scriptive terms for the outcomes of interest, QoL and disease
activity were captured. Systematic searches were conducted in
five electronic databases (Web of Science, PsycINFO
(EBSCO), CINAHL (EBSCO), Embase (Ovid), Medline
(Ovid)) from inception to February 2019, using customized
search terms for each database (See supplementary data 1 for
the Medline search strategy). Reference checking and citation
tracking of index papers were completed. In addition, a search
for grey literature was conducted using “www.opengrey.eu”.
All articles including a population of adults (> 18 years)
with RA, with an exposure of anxiety (reported separately
from depression) and comparator or control group (if any) of
adults with RA, were included. Primary outcome measures
were DAS28 and short-form (SF)-36, with additional validat-
ed outcome measures for disease activity and QoL included,
as detailed in the results. Studies were excluded if they includ-
ed people aged under 18 years, data not specific to anxiety and
RA, if an interpreter could not be found for a paper not written
in the English language or when efforts to retrieve a full text
were unsuccessful and the abstract contained insufficient data.
The SF-36 is a set of patient self-reported QoL measures
that assesses eight health concepts, which can be aggregated
into two summary measures, the Physical (PCS) and Mental
(MCS) Component Summary scores [23]. The SF-36 was
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chosen due to it being acceptable to patients and having high
internal validity [24]. The DAS28 score comprises of bio-
chemical measures (erythrocyte sedimentation rate (ESR) or
C-reactive protein (CRP)), a 28 swollen joint count (SJC) and
tender joint count (TJC), and a patient global assessment
(PtGA) on a Visual Analogue Scale (VAS) [25]. The DAS28
score was selected as a primary outcome measure as it is
commonly used to monitor disease activity and treatment re-
sponse [26].
The full inclusion and exclusion criteria are detailed in
supplementary data 2. Titles, abstracts and full texts were
screened by paired independent reviewers (AM, RH or IS)
using pre-specified selection criteria. Disagreements regard-
ing inclusion were resolved by discussion or the opinion of a
third reviewer.
Data extraction and study quality assessment
A customized and piloted data extraction tool was used to
extract relevant data from the included articles. Extracted data
included country of origin, study design, methodology, sam-
ple characteristics, main findings and relevant statistical mea-
sures. Data extraction was completed independently by two
researchers, AM and RH, and any disagreements resolved
through discussion. Where only abstracts were available, or
insufficient information was reported, authors were contacted
via email. Study quality was assessed using the Newcastle-
Ottawa Scale [27].
Analysis
Extracted data were synthesized using a narrative synthesis
framework as follows:
1. An idea of how anxiety relates to QoL and disease
activity was developed, to inform decisions about the
review question, studies to include and the interpreta-
tion of findings.
2. A preliminary synthesis of the findings of included
studies was developed. A summary of all the studies
was tabulated, then separate data analysis of primary
and additional outcome measures for QoL and disease
activity performed.
3. Relationships between the studies were explored. For ex-
ample, potential sources of heterogeneity were considered
that could explain differences in study findings.
4. The strength of evidence for drawing conclusions and
generalizing findings to different populations was
assessed, considering methodological quality of included
studies, risk of bias and overall evidence in relation to
each of the specified outcomes.
Furthermore, a meta-analysis of quantitative data on the
primary outcome measures was performed. The associa-
tion between anxiety and the primary outcome measures
(DAS28, SF-36) was most frequently reported cross-sec-
tionally, using correlation coefficients. Therefore, correla-
tion coefficients between anxiety and DAS28 in people
with RA were pooled. From the four studies reporting the
correlation between anxiety and SF-36, two used the PCS
and MCS [28, 29], and two reported correlation coeffi-
cients for all of the SF-36 subscales [30, 31]. Therefore,
correlation coefficients between anxiety and the PCS or
“physical functioning” subscale scores were pooled to give
an overall impression of the association between anxiety
and physical QoL. Correlation coefficients between anxi-
ety and the MCS or “mental health” subscale scores were
pooled to give an overall estimate of the association be-
tween anxiety and mental QoL in people with RA.
As there was evidence of significant heterogeneity be-
tween some of the studies, and due to several studies hav-
ing small sample sizes, a random effects model was used
[32]. Correlation coefficients (r) were converted to Fisher’s
z scores r(z′) and an associated standard error calculated
using the standard formula SE[r(z′)] = √(1/(n − 3)). The
r(z′) values were pooled using the metan command in
Stata (Version 14.0), then transformed back to obtain
pooled r values and plotted together with study-specific
estimates. The Cochran Q statistic was used to assess het-
erogeneity. In addition, the I2 statistic [32] was calculated
to examine the proportion of total variation in study esti-
mates which could be explained by heterogeneity.
Results
Summary of included studies
Figure 1 shows the flow of studies within the review. The
characteristics of the 20 studies identified for inclusion in this
review [28–31, 33–48] are summarized in Table 1 (studies
reporting disease activity outcomes) and Table 2 (studies
reporting QoL outcomes). Included studies involved a total
of 7452 patients, 80% of whom were female, with a mean
age of 53.5 years. Sample sizes within primary studies ranged
from 20 to 2919 with a mean of 372 patients. Sixteen of the
studies were full text articles [28–31, 36–43, 45–48], whilst
four were conference abstracts [33–35, 44]. Fourteen [28–31,
35–37, 40, 42, 44–48] were cross-sectional in design, whilst
six were cohort studies [33, 34, 38, 39, 41, 43]. In terms of
outcomes, eleven of the studies assessed disease activity only
[28–44], six assessed QoL only [30, 31, 45–48] and three
assessed both disease activity and QoL [28, 29, 37]. The
Hospital Anxiety and Depression Scale (HADS) was the most
frequently used tool to identify anxiety.
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The primary outcome measure for disease activity, DAS28,
was reported in nine studies, with a further study reporting
change in DAS28 by ≤ 0.6 or treatment discontinuation due
to inefficacy as outcomes [46]. Additional outcome measures
for disease activity across four studies included the Lansbury
Articular Index (LAI), Thompson Articular Index, Pain VAS
and a composite score comprising of CRP, SJC and TJC and a
Physician’s global assessment.
The primary outcome measures for QoL (SF-36 or the
PCS, MCS or subscale scores of SF-36) were reported in five
studies. Other outcome measures for QoL reported in five
studies included Health-Related QoL (HRQoL) using EQ-
5D, Life Satisfaction Index (LSI), Nottingham Health Profile
(NHP), QoL-RA Scale and World Health Organisation QoL-
BREF (WHOQoL-BREF).
Methodological quality assessment for included
studies
Quality assessment using the Newcastle-Ottawa score is pre-
sented in Tables 1 and 2 (for additional details see supplemen-
tary data 3) suggesting most studies were of moderate meth-
odological quality. Many lacked detail on the representative-
ness of their RA sample [28, 29, 36, 37, 40, 44, 46], or on non-
responders [28–31, 33–38, 41, 43–47], whilst several had
small sample sizes, limiting generalizability [28, 30, 31, 46].
Although most used validated tools to ascertain the exposure,
several did not report if they controlled for potential confound-
ing factors [34, 40, 44, 45]. Several studies relied on self-
reported questionnaires to assess outcome measures, particu-
larly for QoL, which were open to bias, whilst some did not
describe their method of outcome assessment.
All cross-sectional studies apart from one, a conference
abstract [44], included a description of their approach to
statistical analysis, reporting confidence intervals and P
values as appropriate. Across the six included cohort stud-
ies, the length of follow-up varied from 6 months to 5 years
[33, 34, 38, 39, 41, 43].
Association between anxiety and disease activity
in RA
The overall findings of the nine studies that reported the asso-
ciation between anxiety and DAS28, the primary outcome
measure for disease activity, are summarized in Table 1.
These included five cross-sectional [28, 35, 37, 42, 44] and
four cohort [33, 34, 38, 39] studies, involving a total of 4718
participants. From the five cross-sectional studies, three found
a significant correlation [28, 35, 42] and two a non-significant
correlation [37, 44] between anxiety and increased DAS28.
All five of these studies reported correlation coefficients for
the cross-sectional association between anxiety and DAS28,
and results were pooled via meta-analysis. Meanwhile, from
the four cohort studies, two found significant associations be-
tween baseline anxiety and increased DAS28 at 6 and
12 months [34, 39], one showed a significant association at
3 months but not at 9 and 15months [38], whilst another study
found a non-significant association between anxiety and
DAS28 at 6-month follow-up [33].
One further study reported disease activity in terms of non-
response to treatment with methotrexate, being indicated as an
improvement in DAS28 by ≤ 0.6 or treatment discontinuation
due to inefficacy [43]. On multivariable analysis, higher base-
line anxiety was found to significantly predict treatment non-
response after 6 months, OR 1.07 (95% CI 1.03–1.12).
Four studies also reported DAS28 subcomponents [33, 35,
39, 42]. Results suggested anxiety was most significantly as-
sociated with the more subjective assessments of disease ac-
tivity, such as PtGA, Pain VAS and TJC. For example,
Matcham et al.’s cohort study found anxiety to be positively
correlated at baseline and at 1-year follow-up with PtGA, TJC,
SJC and ESR, although this correlation was only significant
for PtGA (r = 0.31, p < 0.05 at baseline, r = 0.43, p < 0.01 at 1-
year follow-up) [39]. Onmultiple regression analysis, baseline
anxiety was also significantly associated with PtGA and TJC
at 1-year follow-up [39]. In another study, Pain VAS and TJC
were significantly higher in people with anxiety although
Fig. 1 Study flowchart
Clin Rheumatol
Ta
bl
e
1
S
um
m
ar
y
of
ch
ar
ac
te
ri
st
ic
s
of
st
ud
ie
s
re
po
rt
in
g
di
se
as
e
ac
tiv
ity
ou
tc
om
e
m
ea
su
re
s
A
ut
ho
r/
ye
ar
/c
ou
nt
ry
St
ud
y
de
si
gn
Sa
m
pl
e
si
ze
(m
:f
)
M
ea
n
ag
e
E
xp
os
ur
e
m
ea
su
re
O
ut
co
m
e
m
ea
su
re
R
es
ul
ts
St
ud
y
qu
al
ity
a
A
l-
Fa
dl
(2
8)
20
14
.E
gy
pt
C
ro
ss
-s
ec
tio
na
l
26
(8
:1
8)
43
.4
H
A
M
-A
D
A
S2
8
H
A
M
A
-A
an
d
D
A
S2
8
r=
0.
47
*
M
ed
iu
m
D
yb
al
l(
33
)
20
18
.U
K
C
oh
or
t
29
19
(7
01
:2
21
8)
57
.3
H
A
D
S-
A
D
A
S2
8
B
as
el
in
e
H
A
D
S-
A
an
d
ch
an
ge
in
D
A
S2
8
6
m
on
th
s
A
dj
us
te
d
b
=
0.
01
(n
.s
.),
95
%
C
I,
−
0.
01
,0
.0
4.
M
ed
iu
m
Fr
ag
ou
lis
(3
4)
20
18
.U
K
C
oh
or
t
84
8
(n
ot
re
po
rt
ed
)
N
ot
re
po
rt
ed
H
A
D
S-
A
D
A
S2
8
H
A
D
S-
A
an
d
D
A
S
28
at
:
-b
as
el
in
e
r=
no
va
lu
e
gi
ve
n*
**
-6
m
on
th
s
r=
0.
23
0*
**
,-
12
m
on
th
s
r=
0.
21
7*
**
M
ed
iu
m
G
ro
ss
o
(3
5)
20
15
.I
ta
ly
C
ro
ss
-s
ec
tio
na
l
20
0
(2
9:
17
1)
62
.4
H
A
D
S-
A
D
A
S2
8
A
nx
ie
ty
vs
.h
ea
lth
y
co
nt
ro
l.
M
ea
n
D
A
S2
8
sc
or
e
(S
D
):
3.
38
(1
.1
8)
vs
.2
.4
8
(0
.7
8)
**
M
ed
iu
m
Ic
hi
ka
w
a
(3
6)
19
95
.J
ap
an
C
ro
ss
-s
ec
tio
na
l
92
(1
6:
76
)
53
.4
B
A
I
Pa
in
V
A
S
A
nx
ie
ty
an
d
Pa
in
V
A
S
r=
0.
43
2*
**
M
ed
iu
m
L
A
I
A
nx
ie
ty
an
d
L
A
I
r=
0.
23
7*
K
ar
ah
an
(3
7)
20
16
.T
ur
ke
y
C
ro
ss
-s
ec
tio
na
l
14
8
(3
2:
11
6)
51
.1
Z
un
g’
s
Se
lf
-R
at
in
g
Sc
al
e
D
A
S2
8
B
A
I
an
d
D
A
S2
8
r=
0.
15
9,
(n
.s
.)
M
ed
iu
m
K
oj
im
a
(2
9)
20
09
.J
ap
an
C
ro
ss
-s
ec
tio
na
l
12
0
(2
2:
98
)
57
.7
H
A
D
S-
A
SJ
C
,T
JC
,C
R
P,
Ph
ys
ic
ia
ns
’
gl
ob
al
as
se
ss
m
en
t
H
A
D
S-
A
an
d
di
se
as
e
ac
tiv
ity
fa
ct
or
lo
ad
in
g
−
0.
10
(n
.s
.)
M
ed
iu
m
K
ui
jp
er
(3
8)
20
18
.
N
et
he
rl
an
ds
C
oh
or
t
28
1
(9
1:
19
0)
53
.0
H
A
D
S-
A
D
A
S2
8
H
A
D
S-
A
an
d
D
A
S2
8
at
:
-3
m
on
th
s,
b
=
0.
04
3*
*,
95
%
C
I,
0.
01
3,
0.
07
3
-9
m
on
th
s,
b
=
0.
01
7
(n
.s
.)
,9
5%
C
I,
0.
01
0,
0.
04
4
-1
5
m
on
th
s,
b
=
0.
01
2,
(n
.s
.)
,9
5%
C
I,
−
0.
02
0,
0.
04
3
H
ig
h
M
at
ch
am
(3
9)
20
16
.U
K
C
oh
or
t
56
(1
2:
44
)
53
.6
H
A
D
S-
A
D
A
S2
8
A
nx
ie
ty
an
d
D
A
S2
8
-B
as
el
in
e,
r=
0.
29
*,
1-
ye
ar
fo
llo
w
-u
p,
r=
0.
33
*
H
ig
h
U
na
dj
us
te
d
b
0.
04
*.
95
%
C
I,
0.
00
,0
.0
7.
A
dj
us
te
d
b
=
0.
02
(n
.s
.),
95
%
C
I,
0.
00
,0
.0
5.
M
iw
a
(4
0)
20
02
.J
ap
an
C
ro
ss
-s
ec
tio
na
l
82
(2
0:
62
)
62
.0
H
A
D
S-
A
V
A
S
A
nx
ie
ty
an
d
V
A
S
(a
)
M
ea
n
ac
tiv
ity
<
0.
5,
r=
0.
29
35
*
(b
)
M
ea
n
ac
tiv
ity
≥
0.
5,
r=
−
0.
02
69
(n
.s
.)
M
ed
iu
m
O
ve
rm
an
(4
1)
20
11
.
N
et
he
rl
an
ds
.
C
oh
or
t
54
5
(1
68
:3
77
)
56
.0
10
-I
te
m
A
nx
ie
ty
Sc
al
e
T
ho
m
ps
on
A
rt
ic
ul
ar
In
de
x
A
nx
ie
ty
an
d
T
ho
m
ps
on
A
rt
ic
ul
ar
In
de
x
b(
SE
)=
55
.1
73
6
(2
1.
07
31
)*
*
M
ed
iu
m
E
SR
A
nx
ie
ty
an
d
E
SR
,b
(S
E
)=
0.
24
48
(0
.0
75
9)
**
R
uh
al
ia
(4
2)
20
18
.
M
al
ay
si
a
C
ro
ss
-s
ec
tio
na
l
18
9
(2
2:
16
7)
49
.6
D
A
SS
(2
1)
D
A
S2
8
D
A
SS
(2
1)
an
d
D
A
S2
8
r=
0.
23
3*
*
M
ed
iu
m
Se
rg
ea
nt
(4
3)
20
18
.U
K
C
oh
or
t
10
50
(3
43
:7
07
)
59
.0
H
A
D
S-
A
N
on
-r
es
po
ns
e
to
tr
ea
tm
en
t
(i
m
pr
ov
em
en
ti
n
D
A
S2
8
≤
0.
6/
di
sc
on
tin
ua
tio
n
du
e
to
in
ef
fi
ca
cy
)
H
A
D
S-
A
an
d
no
n-
re
sp
on
se
at
6
m
on
th
s
-M
ul
tiv
ar
ia
bl
e
an
al
ys
is
O
R
(9
5%
C
I)
=
1.
07
(1
.0
3,
1.
12
)*
*
H
ig
h
Z
ul
ge
re
l(
44
)
20
14
.R
us
si
a
C
ro
ss
-s
ec
tio
na
l
51
(2
:4
9)
43
.0
Sp
ie
lb
er
g
C
he
nn
ai
D
A
S2
8
A
nx
ie
ty
an
d
D
A
S2
8
r=
0.
12
6
(n
.s
.)
L
ow
r
Pe
ar
so
n’
s
co
rr
el
at
io
n
co
ef
fi
ci
en
t,
b
m
ul
tip
le
re
gr
es
si
on
co
ef
fi
ci
en
t,
C
I
co
nf
id
en
ce
in
te
rv
al
,
SE
st
an
da
rd
er
ro
r,
O
R
od
ds
ra
tio
,
SD
st
an
da
rd
de
vi
at
io
n,
n.
s.
no
t
si
gn
if
ic
an
t,
(p
>
0.
05
),
*(
p
<
0.
05
),
**
(p
<
0.
01
),
**
*(
p
<
0.
00
1)
B
A
IB
ec
k’
s
A
nx
ie
ty
In
ve
nt
or
y,
C
R
P
C
-r
ea
ct
iv
e
pr
ot
ei
n,
D
A
S2
8
D
is
ea
se
A
ct
iv
ity
S
co
re
in
28
Jo
in
ts
,D
A
SS
21
D
ep
re
ss
io
n,
A
nx
ie
ty
an
d
St
re
ss
Sc
al
e,
E
SR
E
ry
th
ro
cy
te
S
ed
im
en
ta
tio
n
R
at
e,
H
A
D
S
H
os
pi
ta
l
A
nx
ie
ty
an
d
D
ep
re
ss
io
n
Sc
or
e,
H
A
M
-A
H
am
ilt
on
A
nx
ie
ty
R
at
in
g
S
ca
le
,L
A
I
L
an
sb
ur
y’
s
A
ct
iv
ity
In
de
x,
R
A
R
he
um
at
oi
d
A
rt
hr
iti
s,
SJ
C
Sw
ol
le
n
Jo
in
t
C
ou
nt
,S
TA
I
S
pi
el
be
rg
er
S
ta
te
an
d
T
ra
it
A
nx
ie
ty
In
ve
nt
or
y,
TJ
C
Te
nd
er
Jo
in
tC
ou
nt
,V
A
S
V
is
ua
lA
na
lo
gu
e
Sc
al
e
a
Q
ua
lit
y
ra
te
d
ou
to
f
9
us
in
g
N
ew
ca
st
le
-O
tta
w
a
S
ca
le
:0
–2
=
lo
w
qu
al
ity
,3
–6
=
m
ed
iu
m
qu
al
ity
an
d
7–
9
=
hi
gh
qu
al
ity
Clin Rheumatol
Ta
bl
e
2
S
um
m
ar
y
of
ch
ar
ac
te
ri
st
ic
s
of
st
ud
ie
s
re
po
rt
in
g
Q
oL
ou
tc
om
e
m
ea
su
re
s
A
ut
ho
r/
ye
ar
/c
ou
nt
ry
St
ud
y
de
si
gn
Sa
m
pl
e
si
ze
(m
:f
)
M
ea
n
ag
e
E
xp
os
ur
e
m
ea
su
re
O
ut
co
m
e
m
ea
su
re
R
es
ul
ts
St
ud
y
qu
al
ity
a
A
l-
Fa
dl
[2
8]
20
14
.E
gy
pt
C
ro
ss
-s
ec
tio
na
l
26
(8
:1
8)
43
.4
H
A
M
-A
PC
S/
M
C
S
A
nx
ie
ty
an
d
PC
S
of
SF
-3
6,
r=
−
0.
38
*
A
nx
ie
ty
an
d
M
C
S
of
SF
-3
6,
r=
−
0.
34
*
M
ed
iu
m
A
lp
i(
45
)
20
16
.C
ol
om
bi
a
C
ro
ss
-s
ec
tio
na
l
62
(3
:5
9)
59
.7
H
A
D
S-
A
Q
oL
-R
A
Sc
al
e
A
nx
ie
ty
an
d
Q
oL
-R
A
Sc
al
e,
r=
−
0.
64
4*
*
A
nx
ie
ty
an
d
Q
oL
-R
A
su
b-
sc
or
es
;
Ph
ys
ic
al
ab
ili
ty
,r
=
−
0.
49
2*
*,
Su
pp
or
t,
r=
−
0.
45
4*
*
Pa
in
,r
=
−
0.
48
9*
**
,T
en
si
on
,r
=
−
0.
58
1*
*
H
ea
lth
,r
=
−
0.
62
4*
*,
A
rt
hr
iti
s,
r=
−
0.
51
0*
*
Su
pp
or
t,
r=
−
0.
59
3*
*,
M
oo
d,
r=
−
0.
67
4*
*
M
ed
iu
m
A
nx
ie
ty
an
d
Q
O
L
-R
A
,r
eg
re
ss
io
n
co
ef
fi
ci
en
t
b
=
−
0.
45
3
(t
=
−
4.
24
1,
p
=
0.
00
0)
C
el
ik
er
(4
6)
20
01
.T
ur
ke
y
C
ro
ss
-s
ec
tio
na
l
20
(0
:2
0)
46
.6
ST
A
I
L
SI
A
-S
ta
te
(c
ur
re
nt
an
xi
et
y)
an
d
L
SI
,r
=
−
0.
50
05
*
A
-T
ra
it
(l
on
g-
st
an
di
ng
an
xi
et
y)
an
d
L
SI
,
r=
−
0.
51
03
(n
.s
.)
M
ed
iu
m
K
ar
ah
an
(3
7)
20
16
.T
ur
ke
y
C
ro
ss
-s
ec
tio
na
l
14
8
(3
2:
11
6)
51
.1
B
A
I
W
H
O
Q
oL
-B
R
E
F
M
ild
an
xi
et
y
an
d
W
H
O
Q
oL
-B
R
E
F–
n.
s.
M
od
er
at
e
to
se
ve
re
an
xi
et
y
an
d
W
H
O
Q
oL
-B
R
E
F–
*
M
ed
iu
m
K
oj
im
a
(2
9)
20
09
.J
ap
an
C
ro
ss
-s
ec
tio
na
l
12
0
(2
2:
98
)
57
.7
H
A
D
S-
A
PC
S/
M
C
S
H
A
D
S-
A
an
d
PC
S
of
SF
-3
6,
r=
−
0.
25
**
H
A
D
S-
A
an
d
M
C
S
of
SF
-3
6,
r=
−
0.
51
**
*
M
ed
iu
m
M
ok
(4
7)
20
12
.C
hi
na
C
ro
ss
-s
ec
tio
na
l
20
0
(4
2:
15
8)
51
.4
C
hi
ne
se
B
ili
ng
ua
l
S
tr
uc
tu
re
d
In
te
rv
ie
w
SF
-3
6
A
nx
ie
ty
vs
no
ps
yc
hi
at
ri
c
di
so
rd
er
s,
m
ea
n
(S
D
)
SF
36
=
31
.2
(1
2.
9)
**
*
vs
.5
6.
6
(2
0)
**
M
ed
iu
m
N
as
(3
0)
20
11
.T
ur
ke
y
C
ro
ss
-s
ec
tio
na
l
42
1
(7
2:
34
9)
50
.2
(r
is
k
of
an
xi
et
y
gr
ou
p)
H
A
D
S-
A
SF
-3
6
H
ig
h-
R
is
k
A
nx
ie
ty
an
d
SF
-3
6
su
bs
ca
le
s.
A
ll*
**
Ph
ys
ic
al
fu
nc
tio
ni
ng
(r
=
−
0.
28
),
ph
ys
ic
al
ro
le
(r
=
−
0.
24
)
B
od
ily
pa
in
(r
=
−
0.
32
),
G
en
er
al
he
al
th
,r
=
−
0.
29
,
V
ita
lit
y
(r
=
−
0.
40
),
So
ci
al
fu
nc
tio
ni
ng
(r
=
−
0.
36
)
E
m
ot
io
na
lr
ol
e
(r
=
−
0.
23
)
M
en
ta
lh
ea
lth
(r
=
−
0.
48
)
M
ed
iu
m
A
nx
ie
ty
(n
=
16
6)
vs
.w
ith
ou
ta
nx
ie
ty
(n
=
25
5)
.
SF
-3
6
su
bs
ca
le
s,
ad
ju
st
ed
O
R
(9
5%
C
I)
,s
ig
ni
fi
-
ca
nt
in
ita
lic
s.
P
hy
si
ca
lf
un
ct
io
ni
ng
,0
.9
91
(0
.9
83
,0
.9
99
),
Ph
ys
ic
al
ro
le
,0
.9
94
(0
.9
98
,1
.0
01
),
B
od
ily
pa
in
,0
.9
90
(0
.9
71
,
1.
00
1)
,G
en
er
al
he
al
th
,0
.9
87
(0
.9
77
,0
.9
98
),
Vi
ta
lit
y,
0.
97
2
(0
.9
61
,0
.9
84
),
So
ci
al
fu
nc
tio
ni
ng
,0
.9
84
,
(0
.9
75
,0
.9
95
),
E
m
ot
io
na
lr
ol
e,
0.
99
2
(0
.9
86
,0
.9
98
)
M
en
ta
lh
ea
lth
,0
.9
66
(0
.9
54
,0
.9
77
)
R
A
-Q
oL
A
nx
ie
ty
(n
=
16
6)
vs
.w
ith
ou
ta
nx
ie
ty
(n
=
25
5)
,R
A
-Q
oL
,
O
R
(9
5%
C
I)
=
1.
06
0
(1
.0
32
,1
.0
88
)
N
H
P
A
nx
ie
ty
(n
=
16
6)
vs
.w
ith
ou
ta
nx
ie
ty
(n
=
25
5)
,
N
H
P
su
bs
ca
le
s,
O
R
(9
5%
C
I)
.S
ig
ni
fi
ca
nt
in
ita
lic
s.
P
ai
n,
1.
01
1
(1
.0
04
,1
.0
18
),
P
hy
si
ca
lm
ob
ili
ty
1.
01
7
(1
.0
09
,1
.0
25
),
E
ne
rg
y,
1.
01
5
(1
.0
09
,1
.0
21
),
Sl
ee
p
1.
01
8
(1
.0
11
,1
.0
25
),
So
ci
al
is
ol
at
io
n,
1.
01
7
(1
.0
11
,
1.
02
3)
,E
m
ot
io
na
lr
ea
ct
io
n,
1.
02
6
(1
.0
19
,1
.0
33
)
Clin Rheumatol
there was no significant difference in ESR or SJC [35]. A
further study found anxiety to be significantly correlated with
increased Pain VAS (r = 0.341, p < 0.001) and TJC (r = 0.197,
p = 0.007), but not SJC (r = 0.060, p = 0.412) (51). Dyball
et al. [33] found baseline anxiety to be associated with smaller
improvements in PtGA at 6 months (b = 0.74, 95% CI 0.32,
1.26, p = 0.001) [33].
Four studies reported additional disease activity outcome
measures, detailed in Table 1. These included one cohort study
[41] and three cross-sectional studies [29, 36, 40], involving
839 patients. Overall, anxiety was associated with ESR [41],
the Thompson articular index [41], LAI [33], pain VAS [36]
and VAS as a measure of arthralgia, in individuals with lower
mean activity [40]. However, one study found no association
between anxiety and disease activity, when assessed using a
combination of the physician’s global assessment, TJC, SJC
and CRP [29], potentially reflecting discrepancies between
patient and physician global assessments.
Relationship between anxiety and QoL in RA
The findings of the five studies reporting SF-36 [28–31, 47]
are summarized in Table 2. These were all cross-sectional
studies and involved 801 patients. In the majority of studies,
anxiety had a significant negative association with SF-36 and
its subscale scores indicating worse QoL.
In particular, a significant negative correlation was reported
between anxiety and the PCS and MCS of SF-36 [28, 29]. A
further study found a significant negative correlation between
anxiety and all SF-36 subscale scores apart from emotional
role [31]. Another study found a significant negative correla-
tion between high-risk anxiety and all SF-36 subscales [30],
whilst a comparison of RA patients with and without anxiety
found that all SF-36 subscale scores apart from physical role
and bodily pain were significantly worse in patients with anx-
iety. One study also reported mean SF-36 scores to be signif-
icantly worse in people with anxiety compared with those
without a psychiatric disorder [47]. Four of these studies re-
ported correlation coefficient between anxiety and SF-36 and
its subscales [28–31], hence these were pooled via meta-
analysis.
Different QoL outcome measures were reported in five
studies [30, 37, 45, 46, 48], which are summarized in
Table 2. These were all cross-sectional studies, involving
759 patients. A significant negative correlation was found
between moderate or severe anxiety and the Turkish version
of WHOQoL-BREF score [37]. Current anxiety and the LSI
[46], EQ-5D [48] and QoL-RA Scale [45] also had a signifi-
cant negative correlation. In addition, multiple regression
analysis found anxiety, when measured using the QoL-RA
Scale negatively impacted on QoL [45]. Patients with anxiety
also reported significantly worse NHP subscale scores, andT
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RA-QoL subscale scores [30], compared with those without
anxiety.
Meta-analysis
Figure 2 shows the variation in correlation coefficients across
studies for DAS28, physical and mental QoL outcomes. There
was evidence of significant heterogeneity between studies for
physical QoL (Q statistic p = 0.003; I2 = 78.5%), with relative-
ly lower heterogeneity between studies for mental QoL (p =
0.341; I2 = 10.3%) and DAS28 (p = 0.427; I2 = 0%). The
strongest pooled association was found between anxiety and
worse mental QoL (pooled r (CI) = − 0.50 (− 0.57, − 0.43)).
Strength of evidence
The overall strength of evidence for the relationship between
anxiety in RA and disease activity and QoL has been
reviewed in Table 3, using the Modified Grading of
Recommendations Assessment, Development and
Evaluation (GRADE) system [49]. Most studies reporting
disease activity outcomes had consistent effect sizes, moder-
ate sample sizes and controlled for confounding factors,
whilst heterogeneity on meta-analysis of the correlation be-
tween anxiety and DAS28 was low. Therefore, the strength
of evidence for the association between anxiety and disease
activity was felt to be moderate. Meanwhile, although effect
sizes were relatively consistent for QoL outcomes, almost
half of the studies had small sample sizes and there was
significant heterogeneity on meta-analysis of physical QoL,
meaning the overall strength of evidence for the association
between anxiety and QoL was low.
Discussion
This is the first systematic review to examine the relationship
between anxiety and QoL and disease activity in patients with
RA. Findings suggest that anxiety is associated with increased
disease activity and reduced QoL.
This systematic review demonstrates that anxiety in pa-
tients with RA is associated with increased disease activity,
both cross-sectionally and at 3 months [38], 6 months [34] and
12 months [39] follow-up. These findings complement previ-
ous research, showing that depression in RA is associatedwith
increased disease activity [8].
Whilst one study (involving 52 participants) found the im-
pact of baseline anxiety on disease activity to increase be-
tween 6- and 12-month follow-up [39], two larger studies
(involving 281 and 848 participants) found the impact of base-
line anxiety to reduce over time [34, 38]. The reasons for this
observation are unclear, with Kuijper et al. [38] hypothesising
that in early RA, when treatment has not yet been optimized,
anxiety could influence subjective components of DAS28,
whilst once disease is better controlled, patients may adapt
to living with RA, leading to a reduction in anxiety.
This review suggests the association between anxiety and
increased disease activity may, in part, be due to people with
anxiety reporting higher PtGA scores and other subjective
measures of disease activity [33, 35, 39, 42], rather than an
objective increase in disease activity.
Considering QoL outcomes, this systematic review also
demonstrates that anxiety in patients with RA is cross-
sectionally associated with reduced QoL, complementing
Al-Fadl [28] 2014.
Karahan [37] 2016.
Matcham [39] 2016.
Zulgerel [44] 2014
Overall (I-squared = 0%, p= 0.427)
NOTE: Weights are from random eﬀects analysis
First Author/ Year
n= number of parcipants
r (95% CI)
0.47 (0.10, 0.73)
0.16 (-0.00, 0.31)
0.29 (0.03, 0.51)
0.13 (-0.16, 0.39)
0.23 (0.09, 0.36)Ruhalia [42] 2018.
0.23 (0.14, 0.31)
n= 26
n= 148
n= 56
n= 189
n= 51
a : Anxiety and DAS28
Kojima [29] 2009.
Overall (I-squared = 78.5%, p= 0.003)
NOTE: Weights are from random eﬀects analysis
r (95% CI)
-0.38 (-0.67, 0.01)
-0.25 (-0.41, -0.07)
-0.28 (-0.37, -0.19)
-0.67 (-0.82, -0.43)
-0.39 (-0.57, -0.20)
: Anxiety and Physical QoL
First Author/ Year
n= number of parcipants
n= 26
Al-Fadl [28] 2014.
n= 421
n= 34
Nas [30] 2011.
Ozcen [31] 2007.
n= 120
Al-Fadl [28] 2014.
Kojima [29] 2009.
Nas [30] 2011. 
Ozcen [31] 2007.
Overall (I-squared = 10.3%, p= 0.341)
NOTE: Weights are from random eﬀects analysis
r (95% CI)
-0.34 (-0.64, 0.05)
-0.51 (-0.63, -0.36)
-0.48 (-0.55, -0.46)
-0.65 (-0.81, -0.41)
-0.50 (-0.57, -0.43)
a: Anxiety and Mental QoL
First Author/ Year
n= number of parcipants
n= 26
n= 120
n= 421
n= 34
b
c
Fig. 2 Forest plots of the meta-analysis of correlation coefficients be-
tween A: Anxiety and DAS28, B: Anxiety and Physical QoL and C:
Anxiety and Mental QoL
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previous research showing that depression in RA is associated
with poorer QoL [17]. The largest impact of anxiety on SF-36
subscales was seen on the vitality, social functioning and men-
tal health components [30, 31]. Effect sizes for reduced social
functioning and mental health scores could be interpreted as
symptoms of anxiety as well as components of QoL, whilst
the correlation between anxiety and vitality scores could be
further confounded by associations of mood problems and
fatigue in RA [50] likely to impact negatively on QoL.
A number of strengths and limitations need to be consid-
ered when interpreting the results. The search strategy was
kept broad; hence, we are confident that all available evidence
on this topic has been considered. However, nine potentially
relevant studies could not be included as the published con-
ference abstracts lacked sufficient data, and the authors did not
respond to requests to provide additional data. Furthermore,
twelve articles had to be excluded as anxiety was not reported
separately from depression as an outcome. As anxiety fre-
quently exists in isolation, future studies should consider
reporting anxiety and depression separately, to enable their
individual effects to be analyzed.
Meta-analysis was limited by the small number of studies
which provided suitable data to enable statistical pooling of
results. Where pooled estimates of correlation were obtained,
these, as well as the associated measures of extent of hetero-
geneity, should be interpreted with caution. Potential sources
of heterogeneity were differences in the source populations,
sampling methods and adjustments made for confounding
factors between studies. In the future, availability of suitable
data may allow the impact of individual factors on the out-
comes to be investigated using meta-regression analysis.
All available evidence regardless of the methodological
study quality was incorporated within this review. Overall,
the quality of the included studies was varied. Several poten-
tial sources of bias were identified in terms of the sampling
methods, sample sizes, method of outcome measurement and
loss of participants to follow-up.
Clinicians should consider reviewing DAS28 subcompo-
nents in patients who fail to respond to treatment, especially if
subjective measures (PtGA, TJC) are high relative to more
objective scores (SJC, ESR), since this could indicate under-
lying mood problems rather than high disease activity due to
Table 3 Strength of evidence for association between anxiety, disease activity and QoL outcomes
Outcome Evidence base Strength of association Strength of evidence
(GRADE)a.b
Comments
Disease activity 14 studies
n = 6607
8 cross-sectional
(28, 29, 35–37,
40, 42, 44)
6 cohort (33, 34, 38,
39, 41, 43)
Meta-analysis
Anxiety correlation with DAS28
Pooled r (CI) = 0.23 (0.14, 0.31)
Narrative synthesis
Correlation between anxiety and increased
disease activity
- 7 studies significant
- 3 studies non-significant
Association between anxiety and increased
disease activity
- 2 studies significant baseline to 12 M
- 1 study significant 3 M,
non-significant 9 M/15 M
- 1 study non-significant 6 M
Moderate
⊕⊕⊕
Most studies had consistently
small/moderate effect sizes, a
reasonable sample size and con-
trolled for confounding factors.
There was low heterogeneity in
the meta-analysis.
Quality of life 9 Studies
n = 1139
All cross-sectional
(28–31, 37,
45–48)
Meta-analysis
Anxiety correlation with Physical QoL
Pooled r (CI) = − 0.39 (− 0.57, − 0.20)
Anxiety correlation with Mental QoL
Pooled r (CI) = −0.50 (− 0.57, − 0.43)
Narrative synthesis
Correlation between anxiety and reduced QoL
- 6 studies significant
- 1 study non-significant with mild anxiety but
significant with moderate/severe anxiety
- 1 study non-significant with long-standing
anxiety but significant with current anxiety
Low
⊕⊕
Most studies had consistently
small/moderate effect sizes,
though nearly half of the studies
had small sample sizes and there
was significant heterogeneity on
meta-analysis of mental QoL,
limiting strength of evidence.
a GRADE assessment included risk of bias, inconsistency, indirectness, imprecision, large effect (strength of association) and dose-response gradient
b Symbols for quality of evidence: ⊕⊕⊕⊕High, further research is unlikely to change our confidence in the estimate of effect; ⊕⊕⊕ Moderate,
further research is likely to have an important impact on our confidence in the estimate of effect andmay change it;⊕⊕ Low, further research is likely to
have an important impact on our confidence in the estimate of effect and is likely to change the estimate; ⊕Very low, any estimate of effect is very
uncertain
Clin Rheumatol
inflammation, and as such managing mood alongside inflam-
mation could lead to improved outcomes.
In conclusion, comorbid anxiety in patients with RA is
associated with increased disease activity, poorer treatment
outcomes and reduced QoL. Better identification and manage-
ment of comorbid anxiety by patients and clinicians has the
potential to improve outcomes for people with RA.
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